BPC-157 and TB-500 are the two compounds most often discussed together in the tissue-repair literature, and they are frequently researched as a pair. They arrive from very different starting points — one a synthetic pentadecapeptide derived from a sequence in human gastric juice, the other a fragment of an abundant actin-binding protein — and they sit on different regulatory footings in the UK. What they share is an evidence grade: both are graded Limited on Peptide Data. This explainer sets out what each compound is, where its evidence actually comes from, and why the same grade hides two quite different literatures.
1. Two different molecules
BPC-157 (body protection compound 157) is a synthetic 15-amino-acid pentadecapeptide derived from a sequence found in human gastric juice [R1]. It is not a fragment of a human hormone or a cytokine; its interest to researchers comes from the breadth of preclinical models in which it has been studied.
TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein involved in cell motility and tissue repair [R4]. The designation "TB-500" does not describe one fixed sequence: research forms span roughly 7 to 43 amino acids, all retaining the actin-binding LKKTET motif that gives the parent protein its function [R4][R6].
2. Mechanism: a defined target versus a characterised pathway
The two compounds work through different biology.
Tβ4 — and therefore TB-500 — has a comparatively well-defined molecular mechanism. It sequesters G-actin through the LKKTET motif, regulating actin polymerisation, which is central to cell migration and motility; it also promotes angiogenesis and supports cell survival through integrin-linked kinase (ILK) activation [R4][R5]. Actin sequestration is a specific, measurable interaction, and it is why Tβ4 is described in the literature as an actin-binding protein rather than simply a "repair" peptide.
BPC-157's mechanism is characterised but less precisely localised. Research suggests it upregulates growth hormone receptor expression in tendon fibroblasts, promotes fibroblast proliferation and collagen synthesis, enhances angiogenesis via VEGFR2, and modulates the nitric oxide system [R1][R3]. These are plausible and repeatedly observed effects, but the literature does not converge on a single molecular target in the way the Tβ4 literature does.
That asymmetry matters when reading claims about either compound: a named target is not the same thing as a demonstrated clinical benefit, but it does make the mechanism easier to interrogate.
3. The evidence base: deep preclinical columns, near-empty human ones
BPC-157. The preclinical record is extensive and unusually consistent. Animal models show accelerated healing of tendon, ligament and muscle tissue, gastroprotective effects against gastric ulcers and NSAID-induced damage, and emerging signals in nerve regeneration and wound healing [R1][R2][R3]. Systematic reviews of the preclinical evidence describe consistent effects across models. What the record does not contain is published human clinical trials: there are no randomised controlled trials in humans, and no human pharmacokinetic data to anchor the animal findings to human biology.
TB-500 / thymosin beta-4. The parent protein has a similarly deep animal literature. Tβ4 promotes angiogenesis and accelerated wound healing in animal models [R4], and activates ILK to promote cardiac cell migration, survival and repair after experimental myocardial infarction in mice [R5]. A small number of human studies exist — most notably ophthalmic research into Tβ4 in corneal wound healing and dry eye — but no large-scale human trial of TB-500 for musculoskeletal applications has been published [R6][R7].
In short: both compounds are supported by a substantial preclinical column and a very thin human one. The difference is one of degree — Tβ4 has a handful of human studies in an ophthalmic indication; BPC-157 has essentially none.
4. Why both grade Limited
Peptide Data grades every compound on a four-tier scale — Strong, Moderate, Limited, Anecdotal — and the ceiling for the grade is set by human data. Deep and consistent animal evidence can lift a compound to Limited, but it cannot lift it further without controlled human trials; that is why most research peptides sit at Limited while compounds with published human outcome data, such as tesamorelin in visceral adiposity, reach Moderate.
BPC-157 and TB-500 both land at Limited for the same structural reason: consistent preclinical findings, no controlled human outcome data. The grade is a statement about the strength of the evidence, not about the plausibility of the mechanism — and it should be read the same way for both compounds despite the differences described above.
5. UK legal status: where the two diverge
This is the material difference for UK readers, and it is a regulatory one rather than a scientific one.
TB-500 is not a licensed medicine in the UK and is not a controlled substance. It is legal to purchase and possess for research purposes, and Peptide Data's live profile records its UK status as Legal. It has no MHRA marketing authorisation for human use, and products sold by UK vendors are marketed as research chemicals.
BPC-157 is also not a licensed medicine and is not a controlled substance, and possession for bona fide research is not an offence. Peptide Data's live profile nonetheless records its UK status as UK grey area, reflecting a tightening international regulatory posture rather than a change in UK statute. In 2025 the US Food and Drug Administration listed BPC-157 on a compounding risk alert covering unapproved drug products that it considers to pose a direct challenge to its oversight [R8]. That is a US action and does not itself change UK law; it is cited here as jurisdictional contrast, because it signals the direction of travel among regulators.
The UK position for both compounds rests on the same statutes. A peptide without a marketing authorisation cannot lawfully be supplied for human consumption: supplying an unlicensed medicine breaches the Human Medicines Regulations 2012 [R9], and the licensing regime itself sits in the Medicines Act 1968. Neither compound holds an MHRA authorisation, and the MHRA has not issued guidance naming either one specifically.
6. The combination question
BPC-157 and TB-500 are frequently discussed together, and both live profiles note that the pairing appears in community protocols. There is, however, no published human trial of the combination. The rationale for pairing them is mechanistic and complementary — one acting largely through growth-factor and angiogenic signalling, the other through actin dynamics and ILK — rather than clinical. Researchers should treat combination claims as hypotheses extrapolated from separate preclinical datasets, not as findings.
7. Research-use-only
Neither BPC-157 nor TB-500 is a licensed medicine in the UK, and neither is approved for human consumption. This article describes published research findings and UK regulatory status; it is not medical advice, and it does not recommend or describe how either compound should be used in humans. Peptide Data does not provide consumption, dosing or self-administration guidance for any compound.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.